EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Andrew Lassman, Columbia University
ClinicalTrials.gov Identifier:
NCT01257594
First received: December 8, 2010
Last updated: May 3, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)